Heat shock protein-peptide complex (HSPPC)

Tumor-associated antigens carried by tumor-derived heat shock proteins (HSPPCs) represent a personalized approach to cancer immunotherapy. Heat shock proteins, such as gp96, HSP70, and HSP90, are intracellular chaperones that naturally bind to a diverse array of cellular peptides, including those derived from tumor-specific mutations or neoantigens [1]. When these complexes are isolated from a patient's own tumor tissue and administered as a vaccine, they are targeted to professional antigen-presenting cells (APCs) via specific surface receptors, most notably CD91 (LRP1) [4]. This receptor-mediated uptake facilitates the cross-presentation of the chaperoned tumor antigens on both MHC class I and II molecules, thereby activating a broad-spectrum, autologous T-cell response against the malignancy [1, 2]. This mechanism effectively bypasses the need to identify specific tumor antigens for each patient, as the HSPPC naturally contains the entire antigenic fingerprint of the tumor [3]. Clinical trials, particularly with the gp96-based vaccine vitespen (Oncophage), have explored this approach in melanoma, renal cell carcinoma, and glioblastoma, demonstrating a favorable safety profile and evidence of immune activation [2, 3]. [1] Srivastava, P. K. (2002). Annu Rev Immunol. [2] NCI Drug Dictionary: Vitespen. [3] Wood, C., et al. (2008). Lancet. [4] Binder, R. J. (2014). Nat Rev Immunol.

Other names

Tumor-derived heat shock protein-peptide complexHSP-antigen complexAutologous tumor-derived HSPPCgp96-peptide complexHSP70-peptide complexVitespen

Heat shock proteins (HSPs) act as molecular chaperones that bind to tumor-specific peptides. When administered as a vaccine, these complexes are recognized and internalized by professional antigen-presenting cells (APCs) via receptors such as CD91 (LRP1). Once inside the APC, the chaperoned peptides are processed and cross-presented on MHC class I and II molecules, which triggers a robust, polyvalent T-cell mediated immune response against the tumor [1, 4].